Cargando…
Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved
OBJECTIVE: To assess whether the incidence of hospital infection by a resistant microorganism decreased after the implementation of the restrictive measure of the National Health Surveillance Agency for the commercialization of antimicrobials. METHODS: A historical cohort study of medical records of...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Faculdade de Saúde Pública da Universidade de São Paulo
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705550/ https://www.ncbi.nlm.nih.gov/pubmed/31432930 http://dx.doi.org/10.11606/s1518-8787.2019053000879 |
_version_ | 1783445610710433792 |
---|---|
author | da Costa, Josiane Moreira de Moura, Cristiano Soares de Pádua, Cristiane Aparecida Menezes Vegi, Aline Siqueira Fogal Magalhães, Sérgia Maria Starling Rodrigues, Marina Barra Ribeiro, Andréia Queiroz |
author_facet | da Costa, Josiane Moreira de Moura, Cristiano Soares de Pádua, Cristiane Aparecida Menezes Vegi, Aline Siqueira Fogal Magalhães, Sérgia Maria Starling Rodrigues, Marina Barra Ribeiro, Andréia Queiroz |
author_sort | da Costa, Josiane Moreira |
collection | PubMed |
description | OBJECTIVE: To assess whether the incidence of hospital infection by a resistant microorganism decreased after the implementation of the restrictive measure of the National Health Surveillance Agency for the commercialization of antimicrobials. METHODS: A historical cohort study of medical records of adult patients admitted to a general and public hospital from May 2010 to July 2011. A cohort was formed with patients admitted in the period before the restrictive measure for the commercialization of antimicrobials (Phase I) and a second cohort was formed with patients admitted after the implementation of the restrictive measure (Phase II). RESULTS: The instantaneous risk of hospital infection by a resistant microorganism was estimated at seven by 1,000 people-time (95%CI 0.006–0.008) in Phase I, and four by 1,000 people-time (95%CI 0.003–0.005) in Phase II of the study. The differences between the survival curves in the different phases of the study and stratified by age group were also significant (p < 0.05). CONCLUSIONS: The results suggest that the implementation of the restrictive measure of the commercialization of antimicrobials by the National Health Surveillance Agency reduced the incidence of hospital infection by a resistant microorganism. |
format | Online Article Text |
id | pubmed-6705550 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Faculdade de Saúde Pública da Universidade de São Paulo |
record_format | MEDLINE/PubMed |
spelling | pubmed-67055502019-09-17 Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved da Costa, Josiane Moreira de Moura, Cristiano Soares de Pádua, Cristiane Aparecida Menezes Vegi, Aline Siqueira Fogal Magalhães, Sérgia Maria Starling Rodrigues, Marina Barra Ribeiro, Andréia Queiroz Rev Saude Publica Original Article OBJECTIVE: To assess whether the incidence of hospital infection by a resistant microorganism decreased after the implementation of the restrictive measure of the National Health Surveillance Agency for the commercialization of antimicrobials. METHODS: A historical cohort study of medical records of adult patients admitted to a general and public hospital from May 2010 to July 2011. A cohort was formed with patients admitted in the period before the restrictive measure for the commercialization of antimicrobials (Phase I) and a second cohort was formed with patients admitted after the implementation of the restrictive measure (Phase II). RESULTS: The instantaneous risk of hospital infection by a resistant microorganism was estimated at seven by 1,000 people-time (95%CI 0.006–0.008) in Phase I, and four by 1,000 people-time (95%CI 0.003–0.005) in Phase II of the study. The differences between the survival curves in the different phases of the study and stratified by age group were also significant (p < 0.05). CONCLUSIONS: The results suggest that the implementation of the restrictive measure of the commercialization of antimicrobials by the National Health Surveillance Agency reduced the incidence of hospital infection by a resistant microorganism. Faculdade de Saúde Pública da Universidade de São Paulo 2019-08-15 /pmc/articles/PMC6705550/ /pubmed/31432930 http://dx.doi.org/10.11606/s1518-8787.2019053000879 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article da Costa, Josiane Moreira de Moura, Cristiano Soares de Pádua, Cristiane Aparecida Menezes Vegi, Aline Siqueira Fogal Magalhães, Sérgia Maria Starling Rodrigues, Marina Barra Ribeiro, Andréia Queiroz Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved |
title | Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved |
title_full | Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved |
title_fullStr | Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved |
title_full_unstemmed | Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved |
title_short | Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved |
title_sort | restrictive measure for the commercialization of antimicrobials in brazil: results achieved |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705550/ https://www.ncbi.nlm.nih.gov/pubmed/31432930 http://dx.doi.org/10.11606/s1518-8787.2019053000879 |
work_keys_str_mv | AT dacostajosianemoreira restrictivemeasureforthecommercializationofantimicrobialsinbrazilresultsachieved AT demouracristianosoares restrictivemeasureforthecommercializationofantimicrobialsinbrazilresultsachieved AT depaduacristianeaparecidamenezes restrictivemeasureforthecommercializationofantimicrobialsinbrazilresultsachieved AT vegialinesiqueirafogal restrictivemeasureforthecommercializationofantimicrobialsinbrazilresultsachieved AT magalhaessergiamariastarling restrictivemeasureforthecommercializationofantimicrobialsinbrazilresultsachieved AT rodriguesmarinabarra restrictivemeasureforthecommercializationofantimicrobialsinbrazilresultsachieved AT ribeiroandreiaqueiroz restrictivemeasureforthecommercializationofantimicrobialsinbrazilresultsachieved |